Comedolytic effect of topically applied active vitamin D3 analogue on pseudocomedones in the rhino mouse

British Journal of Dermatology

Volumn 155, Issue 5, 2006, Pages 895-901

  Hayashi, N ^a   Watanabe, H ^b   Yasukawa, H ^b   Uratsuji, H ^b   Kanazawa, H ^a   Ishimaru, M ^c   Kotera, N ^b   Akatsuka, M ^b   Kawashima, M ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Maruho Co   (Japan)

^c KAC Co Ltd   (Japan)

Author keywords

Acne vulgaris; Retinoid; Rhino mouse; Utricle; Vitamin D3 analogue

Indexed keywords

22 OXACALCITRIOL; COLECALCIFEROL DERIVATIVE; RETINOIC ACID; RETINOID;

ACNE VULGARIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMEDO; CONTROLLED STUDY; DERMIS; DRUG EFFICACY; DRUG MECHANISM; EPIDERMIS; HISTOPATHOLOGY; HYPERPLASIA; INFLAMMATORY CELL; KERATINOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; TREATMENT OUTCOME; UTRICLE;

ACNE VULGARIS; ANIMALS; CALCITRIOL; DERMATOLOGIC AGENTS; EPIDERMIS; MICE; MICE, HAIRLESS; MICE, INBRED HRS; OINTMENTS; TREATMENT OUTCOME;

EID: 33749860131     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07486.x     Document Type: Article

References (47)

1. Howard A. 'Rhino', an allele of hairless in the house mouse. J Hered 1940; 31:467-70.
2. Davies RE, Austin WA, Logani MK. Hair loss and cyst formation in hairless and rhino mutant mice. Trans NY Acad Sci 1971; 33:680-93.
3. Mann SJ. Hair loss and cyst formation in hairless and rhino mutant mice. Anat Rec 1971; 170:485-99.
4. Sundberg JP. The hairless and rhino mutations, chromosome 14. In: Handbook of Mouse Mutations with Skin and Hair Abnormalities (Sundberg JP, ed.). Boca Raton: CRC Press, 1994; 291-312.
5. Bernerd F, Ortonne JP, Bouclier M et al. The rhino mouse model: the effects of topically applied all-trans retinoic acid and CD271 on the fine structure of the epidermis and utricle wall of pseudocomedones. Arch Dermatol Res 1991; 283:100-7.
6. Gollnick HPM, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology 2003; 206:29-36.
7. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99:469-76.
8. Papa CM. Vitamin A acid topical therapy. In: Acne Update for the Practitioner (Frank SB, ed.). New York: Yorke Medical Books, 1977; 121-35.
9. Peck GL, Olsen TG, Yoder FW et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300:329-33.
10. Peck GL, Olsen TG, Butkus D et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6:735-45.
11. Peck GL, Gross EG. Comparative analysis of two retinoids in the treatment of disorders of keratinization. In: Retinoids: Advances in Basic Research and Therapy (Orfanos CE, Braun-Falco O, Farber EM et al., eds). New York: Springer-Verlag, 1981; 279-86.
12. Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol 1982; 6:710-15.
13. Baden HP, Buxman MM, Weinstein GD, Yoder FW. Treatment of ichthyosis with isotretinoin. J Am Acad Dermatol 1982; 6:716-20.
14. Dicken CH, Bauer EA, Hazen PG et al. Isotretinoin treatment of Darier's disease. J Am Acad Dermatol 1982; 6:721-6.
15. Michel S, Jomand A, Demarchez M. Pharmacology of adapalene. Br J Dermatol 1998; 139:3-7.
16. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980; 605:33-91.
17. Elias PM, Fritsch PO, Lampe M et al. Retinoid effects on epidermal structure, differentiation, and permeability. Lab Invest 1981; 44:531-40.
18. Kubilus J. Modulation of differentiation by retinoids. J Invest Dermatol 1983; 81 (Suppl.): S55-8.
19. Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol 2003; 4:75-80.
20. Sebok B, Bonnekoh B, Kerenyi M, Gollnick H. Tazarotene induces epidermal cell differentiation in the mouse tail test used as an animal model for psoriasis. Skin Pharmacol Appl Skin Physiol 2000; 13:285-91.
21. Elias PM, Williams ML. Retinoids, cancer, and the skin. Arch Dermatol 1981; 117:160-8.
22. Peck GL. Retinoids in clinical dermatology. In: Progress in Diseases of the Skin (Fleischmajer R, ed.), Vol. 1. New York: Grune & Stratton, 1981; 227-69.
23. Zouboulis CC. Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol 2001; 14:303-15.
24. Barker JN, Ashton RE, Marks R et al. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141:274-8.
25. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988; 37:889-95.
26. 3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990; 282:164-7.
27. 3. Endocrinology 1983; 113:1950-7.
28. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86:709-14.
29. Mezick JA, Bhatia MC, Capetola RJ. Topical and systemic effects of retinoids on horn-filled utriculus size in the rhino mouse. A model to quantify 'antikeratinizing' effects of retinoids. J Invest Dermatol 1984; 83:110-13.
30. Sakuta T, Kanayama T. Comedolytic effect of a novel RARgamma-specific retinoid, ER36009: comparison with retinoic acid in the rhino mouse model. Eur J Dermatol 2005; 15:459-64.
31. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997; 36:S96-103.
32. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997; 36:119-25.
33. Gonzalez S, Zonios G, Nguyen BC et al. Endogenous skin fluorescence is a good marker for objective evaluation of comedolysis. J Invest Dermatol 2000; 115:100-5.
34. Brogden RN, Goa KL. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53:511-19.
35. 3 derivatives impair the epidermal permeability barrier in normal mouse skin. Dermatology 1997; 194:151-6.
36. Holmes RL, Williams M, Cunliffe WJ. Pilo-sebaceous duct obstruction and acne. Br J Dermatol 1972; 87:327-32.
37. Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch 1971; 242:12-29.
38. Knaggs HE, Holland DB, Morris C et al. Quantification of cellular proliferation in acne using the monoclonal antibody Ki-67. J Invest Dermatol 1994; 102:89-92.
39. 3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31:21-8.
40. rh) induced by retinoids. J Invest Dermatol 1984; 82:632-5.
41. 3 hormone, on hairless mouse skin in vivo. Br J Dermatol 1995; 132:841-52.
42. 3. J Dermatol Sci 2000; 24:105-11.
43. Kligman LH, Kligman AM. The effect on rhino mouse skin of agents which influence keratinization and exfoliation. J Invest Dermatol 1979; 73:354-8.
44. Harris HH, Downing DT, Stewart ME, Strauss JS. Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol 1983; 8:200-3.
45. 3 suppress lipogenesis in hamster sebaceous gland cells in vitro. J Invest Dermatol 2001; 117:965-70.
46. Effendy I, Kwangsukstith C, Chiappe M, Maibach HI. Effects of calcipotriol on stratum corneum barrier function, hydration and cell renewal in humans. Br J Dermatol 1996; 135:545-9.
47. Tagami H, Tadaki T, Obata M, Koyama J. Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in guinea-pigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol 1992; 127:470-5.